SCYNEXIS Board Approves 1-for-8 Reverse Stock Split, Effective May 29
SCYX sits 20% above its 52-week low of $0.565.
Summary
SCYNEXIS announced its Board of Directors approved a 1-for-8 reverse stock split, effective May 29, 2026, to address Nasdaq listing requirements.
Key Events · Corporate Governance and Compliance · SCYX
-
Board Approves 1-for-8 Reverse Split
The Board of Directors finalized the reverse stock split ratio at 1-for-8, following shareholder approval of a range.
-
Effective Date Set
The reverse stock split will be effective on May 29, 2026, with split-adjusted trading beginning June 1, 2026.
-
Authorized Shares Reduced
The total number of authorized common shares will decrease proportionally from 150,000,000 to 18,750,000.
-
Nasdaq Compliance Action
This action is intended to help the company regain compliance with Nasdaq's minimum bid price requirement.
Analysis · SCYX · Life Sciences
The Board's approval of a 1-for-8 reverse stock split, following shareholder authorization, is a critical step for SCYNEXIS to regain compliance with Nasdaq's minimum bid price requirement. While necessary to maintain listing, reverse splits often reflect underlying challenges and can be perceived negatively by the market. The proportional reduction in authorized shares also aligns with the new share count.
At the time of this filing, SCYX was trading at $0.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $58.1M. The 52-week trading range was $0.57 to $1.31. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.